Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment
Public ClinicalTrials.gov record NCT02873936. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 Weeks in Combination With Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.
Study identification
- NCT ID
- NCT02873936
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 449 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 27, 2016 (Actual)
- Primary completion
- Mar 20, 2018 (Actual)
- Completion
- Jun 26, 2018 (Actual)
- Last update posted
- May 13, 2021
2016 – 2018
United States locations
- U.S. sites
- 55
- U.S. states
- 23
- U.S. cities
- 55
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Gilbert | Arizona | — | — |
| Not listed | Covina | California | — | — |
| Not listed | Hemet | California | — | — |
| Not listed | La Jolla | California | — | — |
| Not listed | Palm Desert | California | — | — |
| Not listed | Palo Alto | California | — | — |
| Not listed | Riverside | California | — | — |
| Not listed | Upland | California | — | — |
| Not listed | Victorville | California | — | — |
| Not listed | Whittier | California | — | — |
| Not listed | Aventura | Florida | — | — |
| Not listed | DeBary | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | Orlando | Florida | — | — |
| Not listed | Plantation | Florida | — | — |
| Not listed | Port Richey | Florida | — | — |
| Not listed | Decatur | Georgia | — | — |
| Not listed | Kansas City | Kansas | — | — |
| Not listed | Wichita | Kansas | — | — |
| Not listed | Elizabethtown | Kentucky | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Cumberland | Maryland | — | — |
| Not listed | Frederick | Maryland | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Saint Clair Shores | Michigan | — | — |
| Not listed | Hattiesburg | Mississippi | — | — |
| Not listed | Tupelo | Mississippi | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Lincoln | Nebraska | — | — |
| Not listed | Lebanon | New Hampshire | — | — |
| Not listed | Freehold | New Jersey | — | — |
| Not listed | Toms River | New Jersey | — | — |
| Not listed | Brooklyn | New York | — | — |
| Not listed | Charlotte | North Carolina | — | — |
| Not listed | Greenville | North Carolina | — | — |
| Not listed | Salisbury | North Carolina | — | — |
| Not listed | Middleburg Heights | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Tulsa | Oklahoma | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Wyomissing | Pennsylvania | — | — |
| Not listed | Charleston | South Carolina | — | — |
| Not listed | Columbia | South Carolina | — | — |
| Not listed | Myrtle Beach | South Carolina | — | — |
| Not listed | Orangeburg | South Carolina | — | — |
| Not listed | Memphis | Tennessee | — | — |
| Not listed | Beaumont | Texas | — | — |
| Not listed | Corpus Christi | Texas | — | — |
| Not listed | Mesquite | Texas | — | — |
| Not listed | Plano | Texas | — | — |
| Not listed | San Antonio | Texas | — | — |
| Not listed | Webster | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02873936, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2021 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02873936 live on ClinicalTrials.gov.